BR0112080A - Vetores particulados para aperfeiçoamento da absorção oral de principios ativos - Google Patents

Vetores particulados para aperfeiçoamento da absorção oral de principios ativos

Info

Publication number
BR0112080A
BR0112080A BR0112080-8A BR0112080A BR0112080A BR 0112080 A BR0112080 A BR 0112080A BR 0112080 A BR0112080 A BR 0112080A BR 0112080 A BR0112080 A BR 0112080A
Authority
BR
Brazil
Prior art keywords
oral absorption
active ingredients
improving oral
particulate vectors
vectors
Prior art date
Application number
BR0112080-8A
Other languages
English (en)
Other versions
BRPI0112080B1 (pt
Inventor
Philippe Maincent
Nathalie Ubrich
Claude Vigneron
Original Assignee
Philippe Maincent
Nathalie Ubrich
Claude Vigneron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philippe Maincent, Nathalie Ubrich, Claude Vigneron filed Critical Philippe Maincent
Publication of BR0112080A publication Critical patent/BR0112080A/pt
Publication of BRPI0112080B1 publication Critical patent/BRPI0112080B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

"VETORES PARTICULADOS PARA APERFEIçOAMENTO DA ABSORçãO ORAL DE PRINCìPIOS ATIVOS". A invenção se refere a vetores particulados designados para aperfeiçoar a absorção oral de princípios ativos, caracterizados em eles consistem de uma matriz de polímero compreendendo pelo menos um polímero biodegradável associado com pelo menos um polímero policatiónico.
BRPI0112080A 2000-07-07 2001-07-05 vetores particulados para aperfeiçoamento da absorção oral de principios ativos BRPI0112080B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0008902A FR2811227A1 (fr) 2000-07-07 2000-07-07 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
PCT/FR2001/002159 WO2002003960A1 (fr) 2000-07-07 2001-07-05 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs

Publications (2)

Publication Number Publication Date
BR0112080A true BR0112080A (pt) 2003-05-06
BRPI0112080B1 BRPI0112080B1 (pt) 2017-01-24

Family

ID=8852251

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0112080A BRPI0112080B1 (pt) 2000-07-07 2001-07-05 vetores particulados para aperfeiçoamento da absorção oral de principios ativos

Country Status (17)

Country Link
US (1) US8052998B2 (pt)
EP (1) EP1313453B1 (pt)
JP (1) JP5175017B2 (pt)
KR (1) KR20030038655A (pt)
CN (1) CN1440277A (pt)
AT (1) ATE395906T1 (pt)
AU (1) AU2002218745A1 (pt)
BR (1) BRPI0112080B1 (pt)
CA (1) CA2415414C (pt)
DE (1) DE60134147D1 (pt)
DK (1) DK1313453T3 (pt)
ES (1) ES2305121T3 (pt)
FR (1) FR2811227A1 (pt)
MX (1) MXPA03000193A (pt)
PT (1) PT1313453E (pt)
RU (1) RU2003103596A (pt)
WO (1) WO2002003960A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257744B2 (en) 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
EP2060253A1 (en) 2007-11-14 2009-05-20 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
EP1615632B1 (fr) * 2003-04-17 2006-12-06 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
CA2596011C (en) * 2005-02-17 2013-05-14 Medivas, Llc Polymer particle delivery compositions and methods of use
CN101180073A (zh) * 2005-04-27 2008-05-14 贾拉尔·梅萨德克 胰岛素组合
US8652504B2 (en) 2005-09-22 2014-02-18 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2009010842A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
EP2213282A1 (en) * 2009-01-30 2010-08-04 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9101547B2 (en) * 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
DE102012019029A1 (de) 2012-09-27 2014-03-27 Alf Lamprecht Arzneiformulierungen zur oralen Gabe von therapeutischen Substanzen und Verfahren zur Herstellung
CA3015172A1 (en) 2016-02-18 2017-08-24 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
WO2018151849A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
CA3220269A1 (en) * 2021-06-01 2022-12-08 Manijeh N. Goldberg Enhanced two-stage microparticle-based localized therapeutic delivery system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
CA2099376A1 (en) * 1991-01-03 1992-07-04 Henry E. Auer Stabilization of proteins by cationic biopolymers
EP0535937B2 (en) * 1991-10-01 2008-05-21 Takeda Chemical Industries, Ltd. Prolonged release microparticle preparation and production of the same
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE4220782A1 (de) * 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
WO1996028143A1 (de) * 1995-03-10 1996-09-19 Boehringer Mannheim Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
FR2769853B1 (fr) * 1997-10-21 2000-01-28 Prographarm Lab Nouveau procede d'obtention de microspheres et les produits ainsi realises
IL143002A0 (en) * 1998-11-12 2002-04-21 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
AU3471400A (en) * 1999-01-19 2000-08-07 Children's Hospital Of Philadelphia, The Compositions and methods for controlled delivery of virus vectors

Also Published As

Publication number Publication date
JP2004502720A (ja) 2004-01-29
KR20030038655A (ko) 2003-05-16
BRPI0112080B1 (pt) 2017-01-24
AU2002218745A1 (en) 2002-01-21
WO2002003960A1 (fr) 2002-01-17
US8052998B2 (en) 2011-11-08
PT1313453E (pt) 2008-07-16
FR2811227A1 (fr) 2002-01-11
EP1313453A1 (fr) 2003-05-28
EP1313453B1 (fr) 2008-05-21
JP5175017B2 (ja) 2013-04-03
CA2415414C (fr) 2011-08-23
CN1440277A (zh) 2003-09-03
DE60134147D1 (de) 2008-07-03
RU2003103596A (ru) 2004-08-20
ATE395906T1 (de) 2008-06-15
ES2305121T3 (es) 2008-11-01
MXPA03000193A (es) 2004-09-13
US20050013866A1 (en) 2005-01-20
DK1313453T3 (da) 2008-09-22
CA2415414A1 (fr) 2002-01-17

Similar Documents

Publication Publication Date Title
BR0112080A (pt) Vetores particulados para aperfeiçoamento da absorção oral de principios ativos
ES2191871T3 (es) Composicion espesada acuosa y utilizacion.
BR0011790B1 (pt) produto absorvente com inibidor de umidade não trançado.
BR9915457B1 (pt) composições de moldagem, uso e artigo.
BR0210005B1 (pt) Polímero, processo para o preparo do mesmo e estrutura absorvente.
BR0115810B1 (pt) composições cosméticas, dermatológicas e farmacêuticas isentas de tensoativos.
IT1320188B1 (it) Gomma da masticare.
BR9906070A (pt) Benzamidas substituìdas
BR0308486A (pt) Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga
DE59902006D1 (de) Wirkstoffhaltige aromatische copolyester
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
BR0004476B1 (pt) recipiente polimérico para combustìvel.
BR0110696B1 (pt) composição polimérica, seu processo de produção, seu uso, processo para produção de corpos moldados de ação antiestática e corpo moldado.
BR0308710A (pt) conjugados poliméricos antimicrobianos
DE60139195D1 (de) Aktivierbare polymerzusammensetzung, und gegenstände, die diese nutzen
BR0015675B1 (pt) composição de gel aerado, estável em armazenagem, e, processo para a produção da mesma.
FR2807321B1 (fr) Nouvel actif, composition le renfermant et utilisation en cosmetique, dermocosmetique, dermopharmacie ou pharmacie ou sur des supports tisses ou non tisses
IT1317841B1 (it) Derivati del 3,9-diazabiciclo(3.3.1)nonano ad attivita' analgesica.
HK1021542A1 (en) Polymer compositions, their preparation and their use.
ATE225391T1 (de) Waschmittelzusammensetzung mit wasserunlöslichem, entfärbungshemmendem polymerwirkstoff
TR200701424T1 (tr) Suda çözünebilen katı dozaj formunda farmasötik bileşim.
IT1318578B1 (it) Articolatore, particolarmente per le applicazioni in odontoiatria eodontotecnica.
RU2000104127A (ru) Штамм bacillus subtilis x-15, используемый для профилактики и лечения эндометритов у коров
RU96115480A (ru) Лекарственное средство, обладающее холелитолитическим действием
ES1041836Y (es) Perfeccionamientos en dispositivos de señalizacion para gradas, peldaños y similares.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL 7: A61K 9/16.

Ipc: A61K 9/26 (2010.01), A61K 31/727 (2010.01), A61K 3

B25G Requested change of headquarter approved

Owner name: NATHALIE UBRICH (FR) , CLAUDE VIGNERON (FR) , PHIL

Free format text: SEDES ALTERADAS CONFORME SOLICITADO NA PETICAO NO 020090091883/RJ DE 29/09/2009.

B25C Requirement related to requested transfer of rights

Owner name: NATHALIE UBRICH (FR) , CLAUDE VIGNERON (FR) , PHIL

Free format text: AFIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020090091883/RJ DE 29/09/2009, APRESENTE DOCUMENTO IDENTIFICANDO A CESSAO PARA O PEDIDO NACIONAL, BEM COMO A LEGALIZACAO CONSULAR.

B25A Requested transfer of rights approved

Owner name: LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES)

Free format text: TRANSFERIDO DE: PHILIPPE MAINCENT, NATHALIE UBRICH E CLAUDE VIGNERON

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/01/2017, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2627 DE 11-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.